% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Abdelmoity:282588,
      author       = {Abdelmoity, Omar and Wisch, Julie K and Kennedy, James T
                      and Goyal, Manu and Vlassenko, Andrei and Flores, Shaney and
                      Handen, Benjamin L and Head, Elizabeth and Keator, David and
                      Rafii, Michael S and Lao, Patrick and Lai, Florence and
                      Rosas, H Diana and Hartley, Sigan L and Zaman, Shahid and
                      Brickman, Adam M and Tudorascu, Dana and Lee, Joseph H and
                      Allegri, Ricardo Francisco and Keefe, Sarah and la Fougère,
                      Christian and Llibre-Guerra, Jorge and Ikeuchi, Takeshi and
                      Morris, John C and Roh, Jee Hoon and Day, Gregory S and
                      Levin, Johannes and Schofield, Peter R and Gordon, Brian A
                      and Benzinger, Tammie L S and Ances, Beau M and Syndrome,
                      Alzheimer's Biomarker Consortium-Down},
      collaboration = {Network, the Dominantly Inherited Alzheimer},
      title        = {{C}ross-{S}ectional {FDG} in {D}own {S}yndrome and
                      {A}utosomal {D}ominant {A}lzheimer's {D}isease.},
      journal      = {Annals of neurology},
      volume       = {98},
      number       = {6},
      issn         = {0364-5134},
      address      = {Hoboken, NJ},
      publisher    = {Wiley-Blackwell},
      reportid     = {DZNE-2025-01348},
      pages        = {1237 - 1248},
      year         = {2025},
      abstract     = {Directly compare the brain glucose patterns seen with
                      [F-18] fluorodeoxyglucose (FDG) positron emission tomography
                      (PET) between 2 genetically determined forms of Alzheimer's
                      disease: Down syndrome (DS) and autosomal dominant
                      Alzheimer's disease (ADAD).Cross-sectional analyses of FDG
                      were performed in individuals with DS (n = 76) from the
                      Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS), ADAD
                      (n = 297), and neurotypical familial controls (n = 188) from
                      the Dominantly Inherited Alzheimer Network (DIAN).
                      Within-group linear regression models and generalized
                      additive models were performed for select regional FDG
                      uptake measures (isthmus cingulate and inferior parietal,
                      precuneus, middle temporal gyrus, and precentral gyrus).
                      Age, sex, apolipoprotein (APOE) ε4 carrier status, and
                      cortical amyloid burden were included within these
                      analyses.Even 20 years before expected onset of clinical
                      symptoms, FDG uptake was lower for DS compared to
                      neurotypical familial controls (p < 0.01). ADAD baseline FDG
                      was similar to neurotypical familial controls until 7 years
                      before expected symptom onset. Both symptomatic individuals
                      with DS and ADAD had lower FDG compared to neurotypical
                      familial controls (p < 0.01). A higher amyloid burden was
                      associated with lower FDG for both genetic forms, with
                      similar rates of decline in FDG uptake for DS and ADAD who
                      were amyloid positive.Brain glucose metabolism is
                      substantially lower for people with DS, even in individuals
                      who are cognitively stable. The patterns of FDG decline are
                      distinct in these 2 genetically determined forms of AD. The
                      diagnostic utility of FDG-PET is specific to the genetic
                      form of AD. ANN NEUROL 2025;98:1237-1248.},
      keywords     = {Humans / Alzheimer Disease: diagnostic imaging / Alzheimer
                      Disease: genetics / Alzheimer Disease: metabolism / Male /
                      Female / Fluorodeoxyglucose F18: metabolism /
                      Cross-Sectional Studies / Down Syndrome: diagnostic imaging
                      / Down Syndrome: metabolism / Down Syndrome: genetics /
                      Positron-Emission Tomography / Middle Aged / Adult / Aged /
                      Brain: diagnostic imaging / Brain: metabolism /
                      Radiopharmaceuticals / Glucose: metabolism /
                      Fluorodeoxyglucose F18 (NLM Chemicals) /
                      Radiopharmaceuticals (NLM Chemicals) / Glucose (NLM
                      Chemicals)},
      cin          = {AG Levin / Clinical Research (Munich) / Tübingen common},
      ddc          = {610},
      cid          = {I:(DE-2719)1111016 / I:(DE-2719)1111015 /
                      I:(DE-2719)6000018},
      pnm          = {353 - Clinical and Health Care Research (POF4-353) / 899 -
                      ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40977577},
      doi          = {10.1002/ana.78002},
      url          = {https://pub.dzne.de/record/282588},
}